New Drug Combo Shows Promise in Lung Cancer Battle

Kelun-Biotech has announced that their Phase III study has shown promising results for a new drug combo in treating a tough form of lung cancer. By replacing standard chemotherapy with a mix of sac-TMT and pembrolizumab, they saw better outcomes for patients with PD-L1-negative non-squamous NSCLC. This success opens up more treatment options for a group that previously had limited choices. What does it mean for you? If you're dealing with or know someone facing this type of lung cancer, this could mean more effective treatment options on the horizon that might improve survival rates and quality of life.